A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 29, 2010

Primary Completion Date

November 5, 2010

Study Completion Date

November 5, 2010

Conditions

Asthma

Interventions

DRUG

GW870086X

5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.

DRUG

Placebo

placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.

Trial Locations (1)

GSK Investigational Site, Berlin